Biotech IV Monitor

LGND — Ligand Pharmaceuticals Incorporated

$6.0B market cap · 1 upcoming readout tracked

Clinical trial readout dates for Ligand Pharmaceuticals Incorporated, compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is April 2027.

Next readoutApril 2027in ~5 months
Upcoming readouts11 Phase 3
Market cap$6.0B
Cash & investments$447M~16 quarters at last loss rate
Recent 8-K filings1latest 2026-10-29

Upcoming readouts

Phase 3 Lasofoxifene + abemaciclib
ER+/HER2- breast cancer with an ESR1 mutation
April 2027
Enrollment Initiation

In progress, no date published

Phase 2 AT278-AID System
Diabetes
date not published
Trial Planned

Target dates already passed

These dates have elapsed; the company may have reported, or guidance may have shifted.

Phase 3 ZTALMY (ganaxolone)
Refractory status epilepticus (RSE)
March 30, 2024
Ongoing

Cash position

Ligand Pharmaceuticals Incorporated reported $447M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-10-30). Its net loss for that quarter was $28M; at that rate the cash would last about 16 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.

Recent SEC filings

8-K Results of Operations — earnings, may carry pipeline updates2026-10-29

Companies working on similar indications

Discussion

No messages yet. If you follow LGND, you can start the conversation.
Track LGND in real time
See live implied volatility for LGND and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on LGND
Contact — questions or corrections about LGND: dukeupt@gmail.com